Skip to main content
. 2010;4(2):20–28. doi: 10.4314/ajid.v4i2.55149

Figure 6.

Figure 6

Meta-analysis of Artesunate + Amodiaquine (AS+AQ) Versus Arthemeter-Lumefantrine (AL) (2007–2009)

All studies that satisfied the inclusion criteria and were conducted within January 2007 and June 2009 were included in this analysis. The outcome measure of interest (day 28 parasitological failure) is not clinically desirable; therefore, the right side of the graph favours Arthemeter-Lumefantrine.